北京时间2025年9月8日晚WCLC期间，百济神州公布替雷利珠单抗两项临床研究成果。RATIONALE-315研究针对可切除NSCLC患者围术期治疗，其最终分析显示，新辅助联合化疗序贯辅助治疗方案价值显著，与对照组相比，可降低死亡风险35%，4年EFS率达61.2%，OS率达72.3%，且安全性和耐受性良好，该研究填补了替雷利珠单抗用于NSCLC围手术期治疗的生存数据空白，为免疫治疗向围术期拓展...
Source Link北京时间2025年9月8日晚WCLC期间，百济神州公布替雷利珠单抗两项临床研究成果。RATIONALE-315研究针对可切除NSCLC患者围术期治疗，其最终分析显示，新辅助联合化疗序贯辅助治疗方案价值显著，与对照组相比，可降低死亡风险35%，4年EFS率达61.2%，OS率达72.3%，且安全性和耐受性良好，该研究填补了替雷利珠单抗用于NSCLC围手术期治疗的生存数据空白，为免疫治疗向围术期拓展...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.